Does BELANTAMAB MAFODOTIN-BLMF Cause Therapy cessation? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Therapy cessation have been filed in association with BELANTAMAB MAFODOTIN-BLMF. This represents 4.0% of all adverse event reports for BELANTAMAB MAFODOTIN-BLMF.
6
Reports of Therapy cessation with BELANTAMAB MAFODOTIN-BLMF
4.0%
of all BELANTAMAB MAFODOTIN-BLMF reports
3
Deaths
0
Hospitalizations
How Dangerous Is Therapy cessation From BELANTAMAB MAFODOTIN-BLMF?
Of the 6 reports, 3 (50.0%) resulted in death.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BELANTAMAB MAFODOTIN-BLMF. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does BELANTAMAB MAFODOTIN-BLMF Cause?
Death (32)
Plasma cell myeloma (15)
Keratopathy (11)
Visual impairment (11)
Ocular toxicity (10)
Condition aggravated (9)
Plasma cell myeloma refractory (9)
Disease progression (7)
Dry eye (7)
Fatigue (7)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which BELANTAMAB MAFODOTIN-BLMF Alternatives Have Lower Therapy cessation Risk?
BELANTAMAB MAFODOTIN-BLMF vs BELATACEPT
BELANTAMAB MAFODOTIN-BLMF vs BELIMUMAB
BELANTAMAB MAFODOTIN-BLMF vs BELINOSTAT
BELANTAMAB MAFODOTIN-BLMF vs BELUMOSUDIL
BELANTAMAB MAFODOTIN-BLMF vs BELVIQ